TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00878566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced pharmacist care
Description: The primary intervention will be enhanced pharmacist care. Pharmacists will assess patients with regards to cardiovascular risk reduction including reviewing BP control, treatment goals and determining lifestyle modifications for the patient to undertake to help manage their BP. The pharmacist will also review the patient's current hypertensive therapy regimen and decide on the options for improvement of BP control (lifestyle modification, increase dose, additional BP medications), and implementation of these strategies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients randomized to usual care will receive a wallet card for BP readings, pamphlet on BP and usual pharmacist and physician care. Patients will be seen at 12 weeks for interim BP measurement only. Both groups of patients will be seen at 24 weeks for BP measurement.
Study: NCT03627416

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: high frequency rTMS to induce the long term potentiation of primary motor areas for the muscles of lower extremities

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: high frequency rTMS to induce the long term potentiation of primary motor areas for the muscles of lower extremities
Study: NCT03062527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention: Low vs. moderate glycemic index
Study: NCT02088775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: Undergo PET-CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: Undergo PET-CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic artery embolization
Description: Undergo standard radioembolization
Study: NCT00661258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic drug monitoring feedback data
Description: All patients were given electronic drug monitors that can monitor pill-taking behavior. In the intervention arm, patients and their attending doctors were given the electronic drug monitoring data on pill bottle openings at each monthly visit for use in adherence counseling sessions. Control arm patients were not given their electronic drug monitoring feedback data and their counseling sessions were based on self-reported adherence, as per standard of care in Dali.
Study: NCT03501693

Intervention type: DEVICE
Intervention: DBT plus S-View
Description: DBT plus S-View images
Study: NCT03384784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER. The dosing regimen will be an initial 4 weeks of drug run-up at the lowest 8mg q.d. dose, followed by 16mg q.d. for the following 4 weeks, and the dose will be increased for the last 4 weeks to 24mg. Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) every morning, preferably with food.
Study: NCT03501693

Intervention type: DEVICE
Intervention: FFDM Alone
Description: FFDM alone images
Study: NCT03803020

Intervention type: OTHER
Intervention: fractional flow reserve and SPECT detection
Description: fractional flow reserve and SPECT detection
Study: NCT02938936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-natal visit scheduling
Description: This intervention will include a scheduled date and time for prenatal care follow-up visits. Women in the intervention group seeking care for their first ANC appointment will be offered several appointment slots on their return date by the nurse providing their first ANC visit. Women will be able select among the time options and will be provided an appointment card with their scheduled date and time. Staff will limit the number of scheduled women per hour by maintaining an appointment book. Clinic staff will be trained to differentiate between women returning for a scheduled visit from first prenatal visits, emergencies, and unscheduled return visits. First visits and emergencies will be seen during the first 2 hours after clinic opening and unscheduled women will be seen during a one-hour time slot midday. When women return on their date, they will be seen within one hour of their appointment time by clinic staff.
Study: NCT02383511

Intervention type: DRUG
Group type: OTHER
Intervention: SMT C1100
Description: Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID

Intervention type: DRUG
Group type: OTHER
Intervention: SMT C1100
Description: Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID

Intervention type: DRUG
Group type: OTHER
Intervention: SMT C1100
Description: Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID
Study: NCT02207374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subject will receive either a dose of 0.5 or 1.0 mg of semaglutide once weekly (subcutaneous (s.c.) injection).Treatment duration 56 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subject will receive either a dose of 0.5 or 1.0 mg of semaglutide once weekly (subcutaneous (s.c.) injection).Treatment duration 56 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 inhibitor
Description: Subjects will receive one DPP-4 inhibitor in addition to pre-trial OAD monotherapy, if any, for 56 weeks.
Study: NCT01428804

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Device: Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system) Other Name: Eldith DC - Stimulator (neuroConn GmbH, Ilmenau, Germany)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Device: Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system) Other Name: Eldith DC - Stimulator (neuroConn GmbH, Ilmenau, Germany)
Study: NCT01272882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography monitoring
Description: Chest belt with 16 electrodes connected to the EIT device
Study: NCT02494206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBX258
Description: Once patients are registered for the trial, they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.
Study: NCT03414697

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group received routine rehabilitation treatments including acupuncture, massage, Bobath therapy, and Vojat therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: Injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) (at least 1×10\^7), once every 2 weeks, one course of treatment including two injections within 4 weeks, a total of two courses of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: Injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) (at least 1×10\^7), once every 2 weeks, one course of treatment including two injections within 4 weeks, a total of two courses of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: Injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) (at least 1×10\^7), once every 2 weeks, one course of treatment including two injections within 4 weeks, a total of two courses of treatment.
Study: NCT00802828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine Tablets, 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine Tablets, 40 mg
Study: NCT01860014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant alfa
Description: Curosurf: 100 mg/kg-intratracheal, just after pulmonary hemorrhage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beractant
Description: Survanta: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
Study: NCT03696875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multilevel Guided Discharge Planning
Description: Clinical recommendations and resources activations + scheduling of early visit with the specialist + communication with primary care + written instruction sheet to the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study: NCT00702182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine (Navelbine)
Description: Conventional Schedule Oral Vinorelbine on day 1 and day 8 of a 21 day schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine (Navelbine)
Description: Metronomic Schedule Oral Vinorelbine 3 times a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Daily Oral Erlotinib 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Daily Oral Erlotinib 100 mg
Study: NCT04378660

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial intelligence for polyp detection
Description: Colonoscopy enriched with artificial intelligence tool developed for polyp detection, implemented as a second observer
Study: NCT03511872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic life support training
Description: A course design was made to be consistent with ERC guidelines with local modifications made by emergency professionals in duration, instructor-to-trainee ratio, course materials, methods to deliver these materials theoretically, and the type of the manikin used to practice CPR. One-day-course consisting of 75, 20, 20, 20 minutes for theoretical BLS, chocking, recovery position, the practical representation of BLS scenario respectively followed by 40-minute practical training on BLS skills for each subgroup. Both arms of the study follow the same timeline and no extra time is given to any group.~Same manikins were used for the training and the assessment. On the day of the experiment students in each arm are divided into 4 subgroups of maximum 9 students, each led by two trainers of BLS skills with a maximum ratio of 2 instructors to 9 students per group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic life support training
Description: A course design was made to be consistent with ERC guidelines with local modifications made by emergency professionals in duration, instructor-to-trainee ratio, course materials, methods to deliver these materials theoretically, and the type of the manikin used to practice CPR. One-day-course consisting of 75, 20, 20, 20 minutes for theoretical BLS, chocking, recovery position, the practical representation of BLS scenario respectively followed by 40-minute practical training on BLS skills for each subgroup. Both arms of the study follow the same timeline and no extra time is given to any group.~Same manikins were used for the training and the assessment. On the day of the experiment students in each arm are divided into 4 subgroups of maximum 9 students, each led by two trainers of BLS skills with a maximum ratio of 2 instructors to 9 students per group.
Study: NCT04324255

Intervention type: PROCEDURE
Intervention: LT
Description: Liver transplantation
Study: NCT03384784

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galantamine
Description: The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER. The dosing regimen will be an initial 4 weeks of drug run-up at the lowest 8mg q.d. dose, followed by 16mg q.d. for the following 4 weeks, and the dose will be increased for the last 4 weeks to 24mg. Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) every morning, preferably with food.
Study: NCT01504451

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILR insertion
Description: Insertion of implantable loop recorder

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILR insertion
Description: Insertion of implantable loop recorder

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILR insertion
Description: Insertion of implantable loop recorder

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF ablation
Description: AF ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF ablation
Description: AF ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF ablation
Description: AF ablation
Study: NCT03270813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation training plus RAGE-Control
Description: RAGE-Control is a biofeedback videogame in which players shoot at enemies while avoiding allies. The player's baseline heart rate is taken before the game and entered into the computer. During the game, the player wears a heart rate monitor, and if the player's heart rate rises above baseline, they are unable to shoot. The player must use relaxation skills to decrease their heart rate below the baseline before they can resume play. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the RAGE-Control videogame.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Relaxation training plus Sham Videogame
Description: The Sham videogame is a videogame in which players shoot at enemies while avoiding allies. The player wears a heart rate monitor during the game, but the heart rate does not affect the functioning of the game in any way. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the Sham videogame.
Study: NCT03120208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: • The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.
Description: The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: • The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.
Description: The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.
Study: NCT03384784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.
Study: NCT03120208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The GAD-7 with a discrimination threshold ≥10.
Description: The GAD-7 with a discrimination threshold ≥10.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The GAD-7 with a discrimination threshold ≥10.
Description: The GAD-7 with a discrimination threshold ≥10.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: • Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
Description: Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: • Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
Description: Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
Study: NCT01867294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Management of Therapy Complications
Description: Moisturizer given topically

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Given topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Given topically

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Given topically

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Hydrocortisone
Description: Given topically
Study: NCT03108170

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: perineal massage program
Description: The participant will perform digital massage of her perineal area 5 minutes daily starting four weeks before delivery till her actual labour day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle exercise program
Description: The participant will perform pelvic floor muscle exercise daily starting four weeks before delivery till her actual labour day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational pelvic floor dysfunction prevention program
Description: This educational pelvic floor dysfunction prevention program includes instructions about: control of her weight, adequate cleaning for the perineal area, adequate fluid intake, smoking cessation, right posture and frequency of micturition and adequate ingestion of fiber to avoid constipation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational pelvic floor dysfunction prevention program
Description: This educational pelvic floor dysfunction prevention program includes instructions about: control of her weight, adequate cleaning for the perineal area, adequate fluid intake, smoking cessation, right posture and frequency of micturition and adequate ingestion of fiber to avoid constipation
Study: NCT01621451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin and/or clopidogrel
Description: Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD. In immediate group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin and/or clopidogrel
Description: Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD.~In 2 weeks group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.
Study: NCT04987099

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 550 mg/day Choline
Description: Choline chloride (550 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 25 mg/day Choline
Description: Choline chloride (25 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
Study: NCT03133273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncogramme®
Description: Patient is followed within the usual care for stage 4 colorectal cancer, but an Oncogramme test will be made and chemotherapy will be adapted to the results.
Study: NCT03929159

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood biospecimen collection

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood biospecimen collection
Study: NCT03751800

Intervention type: DRUG
Intervention: Chronic hormonal treatment
Description: Drugs used in this study are described by the physicians during routine gynecological visits
Study: NCT04441684

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample for serological test
Description: Serology tests:~* By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland~* ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA~Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample for serological test
Description: Serology tests:~* By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland~* ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA~Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample for serological test
Description: Serology tests:~* By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland~* ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA~Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed.
Study: NCT00754520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic On Metal
Description: Ceramic on Metal articulation using M2a-38™ mm cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal on Metal
Description: Metal on Metal articulation using M2a-38™ mm cup
Study: NCT04598451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Description: Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Oral prednisone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Oral prednisone tablets
Study: NCT01952106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: play computer game